Compare Amylx Pharmaceuticals Inc (AMLX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Texas Instruments Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Texas Instruments Incorporated trades at $306.71 (market cap $283.46B). The key difference: Texas Instruments Incorporated is far larger — about 143.2× Amylx Pharmaceuticals Inc's market cap, and Texas Instruments Incorporated pays a 1.82% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TXN | |
|---|---|---|
Market Cap | $1.98B | $283.46B |
Sector | Health | Technology |
52-Week High | $18.70 | $332.35 |
52-Week Low | $7.64 | $153.33 |
Enterprise Value | $1.70B | $292.40B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Texas Instruments (TXN) trades at $311.51, up 0.94% today, showing strong technical momentum with a bullish moving average signal. The company reported mixed Q1 2026 earnings, beating expectations with $1.68 EPS versus $1.36 expected, while Q3 and Q4 2025 missed. Recent CFO transition to Julie Knecht signals stable leadership. Revenue grew to $17.68B in 2025 from $15.6B in 2024, with net income margin at 29.11%.
Outlook remains positive with 65 analysts showing 48% buy rating and $310.95 consensus target. Key risks include high valuation multiples (P/E 53.24) and rising debt-to-asset ratio (40.61% in 2025). AI-driven data center demand presents growth opportunity, but competition and macroeconomic pressures warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
